文献速递呼吸危重症与机械通气

危重症谵妄抗精神病药物治疗后的长期结局:MIND-USA随机对照试验

Long-term outcomes after treatment of delirium during critical illness with antipsychotics (MIND-USA): a randomised, placebo-controlled, phase 3 trial.
PubMed 文献 · Lancet Respir Med · 2024-04-30

MIND-USA 3期试验纳入566例ICU谵妄患者,1:1:1随机接受安慰剂、氟哌啶醇或齐拉西酮,随访3个月和12个月。两种药物均未显著改善认知、功能、心理、生活质量或就业结局;各治疗组约三分之一存活者在3个月和12个月时均存在认知损害,超过一半存在妨碍就业的认知或躯体限制。

要点

  • 氟哌啶醇与齐拉西酮均未显著改善谵妄患者3个月和12个月的认知结局。
  • 两组药物也未改善功能、心理、生活质量或就业结局。
  • 不建议对危重症成人谵妄常规使用抗精神病药物。

核心结论

  • 在危重谵妄患者中,氟哌啶醇和齐拉西酮对存活者的认知、功能、心理或生活质量结局均无显著影响。
  • 研究结论提示不应将抗精神病药物常规用于治疗危重症成人的谵妄。

研究设计与样本

  • 研究为MIND-USA研究的预设长期随访,属随机、双盲、安慰剂对照3期试验,在美国16家医院开展。
  • 纳入年龄≥18岁、因呼吸衰竭或脓毒症或心源性休克入住ICU且存在谵妄的成人,共566例随机分组:安慰剂184例、氟哌啶醇192例、齐拉西酮190例。
  • 受试者按1:1:1随机接受静脉安慰剂、氟哌啶醇或齐拉西酮,最长14天。

主要发现

  • 各治疗组约三分之一存活者在3个月和12个月随访时均存在认知损害。
  • 每组超过一半受访存活者在3个月和12个月时存在妨碍就业的认知或躯体限制(或两者兼有)。
  • 未发现氟哌啶醇或齐拉西酮较安慰剂改善功能、心理、生活质量或就业结局的证据。

临床怎么用

  • 对ICU谵妄成人不应常规使用氟哌啶醇或齐拉西酮以期改善长期认知或功能结局。
  • 临床决策应结合抗精神病药物短期获益证据不足及出院时不当续用较常见的情况。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Delirium is common during critical illness and is associated with long-term cognitive impairment and disability. Antipsychotics are frequently used to treat delirium, but their effects on long-term outcomes are unknown. We aimed to investigate the effects of antipsychotic treatment of delirious, critically ill patients on long-term cognitive, functional, psychological, and quality-of-life outcomes. METHODS: This prespecified, long-term follow-up to the randomised, double-blind, placebo-controlled phase 3 MIND-USA Study was conducted in 16 hospitals throughout the USA. Adults (aged ≥18 years) who had been admitted to an intensive care unit with respiratory failure or septic or cardiogenic shock were eligible for inclusion in the study if they had delirium. Participants were randomly assigned-using a computer-generated, permuted-block randomisation scheme with stratification by trial site and age-in a 1:1:1 ratio to receive intravenous placebo, haloperidol, or ziprasidone for up to 14 days. Investigators and participants were masked to treatment group assignment. 3 months and 12 months after randomisation, we assessed survivors' cognitive, functional, psychological, quality-of-life, and employment outcomes using validated telephone-administered tests and questionnaires. This trial was registered with ClinicalTrials.gov, NCT01211522, and is complete. FINDINGS: Between Dec 7, 2011, and Aug 12, 2017, we screened 20 914 individuals, of whom 566 were eligible and consented or had consent provided to participate. Of these 566 patients, 184 were assigned to the placebo group, 192 to the haloperidol group, and 190 to the ziprasidone group. 1-year survival and follow-up rates were similar between groups. Cognitive impairment was common in all three treatment groups, with a third of survivors impaired at both 3-month and 12-month follow-up in all groups. More than half of the surveyed survivors in each group had cognitive or physical limitations (or both) that precluded employment at both 3-month and 12-month follow-up. At both 3 months and 12 months, neither haloperidol (adjusted odds ratio 1·22 [95% CI 0·73-2.04] at 3 months and 1·12 [0·60-2·11] at 12 months) nor ziprasidone (1·07 [0·59-1·96] at 3 months and 0·94 [0·62-1·44] at 12 months) significantly altered cognitive outcomes, as measured by the Telephone Interview for Cognitive Status T score, compared with placebo. We also found no evidence that functional, psychological, quality-of-life, or employment outcomes improved with haloperidol or ziprasidone compared with placebo. INTERPRETATION: In delirious, critically ill patients, neither haloperidol nor ziprasidone had a significant effect on cognitive, functional, psychological, or quality-of-life outcomes among survivors. Our findings, along with insufficient evidence of short-term benefit and frequent inappropriate continuation of antipsychotics at hospital discharge, indicate that antipsychotics should not be used routinely to treat delirium in critically ill adults. FUNDING: National Institutes of Health and the US Department of Veterans Affairs.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. Mart MF, Boehm LM, Kiehl AL, et al. Long-term outcomes after treatment of delirium during critical illness with antipsychotics (MIND-USA): a randomised, placebo-controlled, phase 3 trial. Lancet Respir Med. 2024. PMID: 38701817. doi:10.1016/S2213-2600(24)00077-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。